tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

HOWL Stock Latest News

Werewolf Therapeutics price target lowered to $9 from $10 at BofA
The FlyWerewolf Therapeutics price target lowered to $9 from $10 at BofA
15d ago
HOWL
Werewolf Therapeutics Receives Nasdaq Deficiency Notice
PremiumCompany Announcements
Werewolf Therapeutics Receives Nasdaq Deficiency Notice
27d ago
8K
HOWL
Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating
PremiumRatings
Strategic Expansion and Clinical Potential of Werewolf Therapeutics’ PREDATOR Platform Boosts Buy Rating
29d ago
HOWL
Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
PremiumThe Fly
Werewolf Therapeutics price target lowered to $6 from $8 at Wedbush
1M ago
HOWL
Werewolf Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
Werewolf Therapeutics Reports Q1 2025 Financial Results
1M ago
HOWL
Werewolf Therapeutics files $150M mixed securities shelf
PremiumThe FlyWerewolf Therapeutics files $150M mixed securities shelf
1M ago
HOWL
Werewolf Therapeutics reports Q1 EPS (40c), consensus (43c)
Premium
The Fly
Werewolf Therapeutics reports Q1 EPS (40c), consensus (43c)
1M ago
HOWL
Werewolf Therapeutics Announces Q1 2025 Financial Results
Premium
Company Announcements
Werewolf Therapeutics Announces Q1 2025 Financial Results
1M ago
8K
HOWL
Werewolf Therapeutics presents new preclinical data on IL-10 INDUKINE
PremiumThe Fly
Werewolf Therapeutics presents new preclinical data on IL-10 INDUKINE
1M ago
HOWL
Werewolf Therapeutics appoints Bloom as Chief Business Officer
PremiumThe Fly
Werewolf Therapeutics appoints Bloom as Chief Business Officer
2M ago
HOWL
Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects
PremiumRatings
Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects
3M ago
HOWL
Unlocking Broader Therapeutic Potential: Andrew Fein’s Buy Rating on Werewolf Therapeutics
PremiumRatings
Unlocking Broader Therapeutic Potential: Andrew Fein’s Buy Rating on Werewolf Therapeutics
3M ago
HOWL
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China
PremiumCompany AnnouncementsWerewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China
3M ago
HOWL
Werewolf Therapeutics Reports 2024 Financial Results and Progress
Premium
Company Announcements
Werewolf Therapeutics Reports 2024 Financial Results and Progress
3M ago
HOWL
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c)
Premium
The Fly
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c)
3M ago
HOWL
Werewolf Therapeutics sees cash runway through 2Q26
PremiumThe Fly
Werewolf Therapeutics sees cash runway through 2Q26
3M ago
HOWL
Werewolf Therapeutics Appoints Anil Singhal to Board
PremiumCompany Announcements
Werewolf Therapeutics Appoints Anil Singhal to Board
4M ago
8K
HOWL
Werewolf Therapeutics appoints Anil Singhal to board of directors
PremiumThe Fly
Werewolf Therapeutics appoints Anil Singhal to board of directors
4M ago
HOWL
Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities
PremiumThe Fly
Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities
5M ago
HOWL
Werewolf Therapeutics provides business update, highlights 2025 outlook
PremiumThe FlyWerewolf Therapeutics provides business update, highlights 2025 outlook
5M ago
HOWL
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Premium
Company Announcements
Werewolf Therapeutics Advances Innovative Cytokine Therapies
7M ago
8K
HOWL
Werewolf Therapeutics presents preclinical, clinical data on WTX-330
Premium
The Fly
Werewolf Therapeutics presents preclinical, clinical data on WTX-330
7M ago
HOWL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >